Ipsen Update August 2020
After pausing the MOVE trial back in January, Ipsen re-started it in adult patients.
Today, 25th August 2020, they have announced their results from the global Phase 3 MOVE trial, which will be presented at 2020 Annual American Society for Bone and Mineral Research meeting.
Analysis shows a substantial (62%) reduction in mean annualised new bone growth when treated with palovarotene which is exciting news for the FOP community.
“Results from the third interim analysis of the MOVE trial, the first and only multicenter Phase III study of its kind, comprising the largest interventional study in FOP to date with 107 participants, suggest that palovarotene may be an important therapeutic option in FOP.”
Read the press release here.
For the full media release, as a .pdf, click here.